A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor: Janssen Research & Development, LLC
Study ID: NCT05461209
Phase: PHASE3
Status: Withdrawn

Conditions

Relapsed/ Refractory Multiple Myeloma

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Talquetamab — DRUG
Talquetamab will be administered as subcutaneous injection.
Belantamab Mafodotin — DRUG
Belantamab Mafodotin will be administered as intravenous infusion.

Study Details

The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).

Key Dates

Start date: Oct 20, 2022
Status verified: Aug 2025
Primary completion: Nov 15, 2022
Completion: Oct 31, 2024

Study Design

Enrollment: 0 participants (actual)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: Arm A: Talquetamab
Participants will receive talquetamab subcutaneously (SC).
Active Comparator: Arm B: Belantamab Mafodotin
Participants will receive belantamab intravenously (IV).

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: Up to 1 year 3 months ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
University of Arkansas for Medical Sciences	Little Rock	Arkansas	72205	-

Find similar trials in Little Rock, AR

By research site

University of Arkansas for Medical Sciences· Little Rock, AR